RxDoctor Payments Data

Jonathan Sardina, DO

Internal Medicine · Gloucester, VANPI 1053629535

Payments from drug & device makers

$1,612in general payments, 2019–2025

Across 83 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$299
  • Shield Therapeutics Inc$203
  • Pfizer$166
  • AbbVie$160
  • Lilly USA, LLC$146
  • Abbott$130
  • plus $507 from 11 others

What the payments were for

  • Food & beverage$1,59399%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,612 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$155,525
Medicare patients
352
Services billed
3,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan13$148,042
OzempicSemaglutide110$137,900
JardianceEmpagliflozin93$103,550
EliquisApixaban67$72,550
TrulicityDulaglutide47$49,718
LinzessLinaclotide20$29,466
FarxigaDapagliflozin Propanediol21$24,259
XareltoRivaroxaban25$20,826
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,784
JanuviaSitagliptin Phosphate11$11,964
Spiriva RespimatTiotropium Bromide16$8,634
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$6,961
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$4,993
SymbicortBudesonide/Formoterol Fumarate14$3,744
Atorvastatin Calcium421$3,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$299$137,900110 claims
Boehringer IngelheimJardiance, Spiriva Respimat$47$112,183109 claims
PfizerEliquis$166$72,55067 claims
Lilly USA, LLCTrulicity$146$49,71847 claims
AbbVieLinzess, Synthroid$160$30,93753 claims
AstraZenecaFarxiga, Symbicort$116$28,00335 claims
MerckJanuvia$16$11,96411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Gloucester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →